CD8A and breast carcinoma: On the one hand, a maintenance immunotherapy protocol based on low-dose IL-2 and oral 13-cis retinoic acid (RA) has been shown to increase lymphocytes and NK cell levels as well as CD4+/CD8+ ratio in breast cancer patients with a clinical benefit from chemotherapy.